<DOC>
	<DOCNO>NCT02269189</DOCNO>
	<brief_summary>Safety , tolerability pharmacokinetics follow repeat dos ( 15-day dosing )</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics BIIL 284 BS Adult Pediatric Cystic Fibrosis ( CF ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Male female ≥ 6 year ( pediatric 6 17 year inclusive ; adult ≥ 18 year ) ; minimum weight requirement 20 kg Confirmed diagnosis CF ( positive sweat chloride ≥ 60 milliequivalent ( mEq ) /liter ( pilocarpine iontophoresis ) and/or genotype two identifiable mutation consistent CF accompany one clinical feature CF phenotype Forced expiratory volume one second ( FEV1 ) &gt; 25 % predict ( use prediction equation 's Knudson et al ) Clinically stable evidence acute upper low respiratory tract infection current pulmonary exacerbation within 2 week screen Females child bear potential must negative pregnancy test screening , sexually active , must willing use doublebarrier form contraception duration study The patient patient 's legally acceptable representative must able give informed consent accordance International Conference Harmonization ( ICH ) Good Clinical Practice ( GCP ) guideline local legislation The patient must able swallow BIIL 284 tablet whole Patients take chronic medication must willing continue therapy entire duration study Patients history allergy/hypersensitivity ( include medication allergy ) deem relevant trial judge Investigator Patients participate another study investigational drug ( include BI Trial 543.36 ) within one month 6 halflives ( whichever great ) precede screen visit Patients know substance abuse , include alcohol drug abuse , within 30 day prior screen Female patient pregnant lactating Patients unable comply breakfast requirement prior dose Patients receive IV , oral inhale antibiotic corticosteroid pulmonary exacerbation within 2 week screen Patients start new chronic medication CF within 2 week screen Patients document persistent colonization B. cepacia ( define one positive culture within past year ) Patients clinically significant finding chest xray opinion Investigator preclude patient 's participation trial Patients oxyhemoglobin saturation room air &lt; 90 % pulse oximetry Patients hemoglobin &lt; 9.0 g/dL ; platelet &lt; 100x10**9/L ; prothrombin time ( PT ) &gt; 1.5 time upper limit normal , serum glutamicoxaloacetic transaminase ( ALT ) serum glutamicpyruvic transaminase ( AST ) &gt; 2 time upper limit normal ; creatinine &gt; 1.8 mg/dL ( adult ) &gt; 1.4 mg/dL ( pediatrics ) screen Clinically significant disease medical condition CF CFrelated condition , opinion Investigator , would compromise safety patient quality data . This include significant hematological , hepatic , renal , cardiovascular , neurologic disease . Patients diabetes may participate disease good control prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>